# Regional translational institutes with academic GMP suites and IND teams

Source: https://onco.cc/ideas/idea-fund-translational-institutes-gmp/  
OnCo record `idea-fund-translational-institutes-gmp` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Build a handful of publicly-funded centres where academic discoveries can be manufactured to clinical grade and written up for regulators, so good ideas do not die for lack of a factory and a filing.

## Summary

A network of five to ten regional institutes, each with GMP manufacturing for biologics, cell and gene therapies and radiopharmaceuticals, GLP toxicology partnerships, regulatory-affairs staff who write INDs and clinical trial applications, and phase 1 unit access. Academic teams apply with a candidate and leave with a first-in-human trial. Precedents include Cancer Research UK's Centre for Drug Development (which has taken dozens of academic agents into the clinic), NCATS' TRND and BrIDGs programmes, the Netherlands Cancer Institute's in-house pharmacy, and Fraunhofer's translational centres. Institutes are funded on throughput (INDs filed, trials started) and asset outcomes, not on publications.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: A national network of translational institutes triples the number of academically-originated oncology first-in-human trials per year within five years of full operation and halves the median time from candidate nomination to first patient dosed.
- Rationale: CRUK's Centre for Drug Development and its predecessor have progressed many academic agents, several to approval or licensing, at costs far below industry; academic centres with in-house GMP (Penn, Baylor, NKI, Barcelona) are the places academic cell therapies actually reach patients. The binding constraint is capacity and regulatory expertise, both of which scale with dedicated funding.
- Proposed test: Fund two institutes for five years with throughput targets and compare INDs filed and time-to-first-patient for academic assets in their regions with regions without an institute.
- Maturity: early-clinical
- Actor: policy

## Sources

- NCATS: https://ncats.nih.gov/

## Connected records

- ideas: [A fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks](https://onco.cc/ideas/idea-fund-ind-enabling-fund/), [A global first-in-human network for academic cancer trials with single ethics review](https://onco.cc/ideas/idea-fund-global-academic-phase-one-network/), [A national non-profit contract research organisation for academic oncology trials](https://onco.cc/ideas/idea-fund-public-nonprofit-cro/), [An open engineering platform for academic ADCs and bispecifics](https://onco.cc/ideas/idea-fund-academic-adc-bispecific-platform/), [Hospital-exemption cell therapies at scale, backed by a shared registry](https://onco.cc/ideas/idea-fund-hospital-exemption-registry/), [Scale up public drug development that takes academic assets to phase 1](https://onco.cc/ideas/idea-fund-national-drug-development-office/), [Shared modular GMP facilities for academic personalised vaccines and cell products](https://onco.cc/ideas/idea-fund-shared-personalised-therapy-gmp/), [Two-year translational fellowships that pay scientists to develop their own discovery](https://onco.cc/ideas/idea-fund-translational-fellowships/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Radioligand therapy (beta emitters)](https://onco.cc/technologies/radioligand-therapy/)
- institutions: [Abramson Cancer Center, University of Pennsylvania](https://onco.cc/institutions/penn-abramson/), [Cancer Research UK](https://onco.cc/institutions/cruk/), [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/), [Netherlands Cancer Institute (NKI-AvL)](https://onco.cc/institutions/nki/)
- people: [Paul Workman](https://onco.cc/people/paul-workman/)
- bottlenecks: [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/), [The valley of death between lab and product](https://onco.cc/bottlenecks/b-translational-valley/)

---
JSON: https://onco.cc/api/v1/entities/idea-fund-translational-institutes-gmp.json